TITLE

Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease?

AUTHOR(S)
D'Inc, Renata; Dal Pont, Elisabetta; Di Leo, Vincenza; Benazzato, Luca; Martinato, Matteo; Lamboglia, Francesca; Oliva, Lydia; Carlo Sturniolo, Giacomo
PUB. DATE
August 2008
SOURCE
American Journal of Gastroenterology;Aug2008, Vol. 103 Issue 8, p2007
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: Assessing the clinical course of inflammatory bowel disease (IBD) patients consists of periodical clinical evaluations and laboratory tests. We aimed to assess the role of calprotectin tests in predicting clinical relapse in IBD patients. METHODS: Ninety-seven patients with ulcerative colitis (UC) and 65 with Crohn's disease (CD) in clinical remission were prospectively included in the study. A 10-g stool sample was collected for calprotectin assay. The cutoff level was set at 130 mg/kg of feces. Patients were followed up for 1 yr after the test or until relapse. The cumulative proportion of relapses was estimated by the Kaplan-Meier analysis. Statistics for equality of survival distribution were tested using the log-rank test. RESULTS: The calprotectin test was positive in 44 UC patients and 26 of them relapsed within a year, while 11 of 53 UC patients with a negative calprotectin test relapsed within the same time frame. Thirty CD patients had a positive calprotectin test and 13 of them relapsed within a year, as did 7 of the 35 with a negative test result. A significant correlation emerged between a positive calprotectin test and the probability of relapse in UC patients ( P= 0.000). In CD patients, only cases of colonic CD showed a significant correlation between a positive calprotectin test and the probability of relapse, i.e., 6 colonic CD patients were positive for the calprotectin test and 4 relapsed ( P= 0.02). CONCLUSIONS: Measuring calprotectin may help to identify UC and colonic CD patients at higher risk of clinical relapse.
ACCESSION #
33545346

 

Related Articles

  • Overview On Inflammatory Bowel Disease. EL Sayed, Engy Yousry // Nature & Science;Aug2013, Vol. 11 Issue 8, p1 

    Ulcerative colitis (UC) and Crohn's disease (CD) (collectively termed inflammatory bowel disease (IBD)) are complex disorders reflected by wide variation in clinical practice. Ulcerative colitis is characterized by diffuse mucosal inflammation limited to the colon. Crohn's disease is...

  • Inflammatory bowel disease: past, present, and future. Sands, Bruce E. // Journal of Gastroenterology;Jan2007, Vol. 42 Issue 1, p16 

    Crohn's disease and ulcerative colitis, collectively known as the inflammatory bowel diseases (IBD), are largely diseases of the twentieth century, and are associated with the rise of modern, Westernized industrial society. Although the causes of these diseases remain incompletely understood,...

  • ANORECTAL COMPLICATIONS OF CHRONIC ULCERATIVE COLITIS AND REGIONAL ENTERITIS. Granet, Emil // American Journal of Gastroenterology;May1956, Vol. 25 Issue 5, p472 

    Examines the anorectal complications of chronic ulcerative colitis and regional enteritis. Frequency of the occurrence of anorectal complications in longstanding and severe ulcerative colitis and regional enteritis; Limitation of anorectal complications in regional enteritis to suppurative and...

  • Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens. Danese, Silvio; Papa, Alfredo; Saibeni, Simone; Repici, Alessandro; Malesci, Alberto; Vecchi, Maurizio // American Journal of Gastroenterology;Jan2007, Vol. 102 Issue 1, p174 

    Inflammation and coagulation play crucial roles in the pathogenesis of multiple chronic inflammatory disorders. Growing evidence highlights a tight mutual network in which inflammation, coagulation, and fibrinolysis play closely related roles. Crohn's disease (CD) and ulcerative colitis (UC),...

  • Immune responses triggering colitis and colitis-associated carcinoma. Kesselring, Rebecca; Fichtner-Feigl, Stefan // Langenbeck's Archives of Surgery;Apr2012, Vol. 397 Issue 4, p527 

    Inflammatory bowel diseases compromise of two forms of chronic intestinal inflammatory disorders: Crohn's disease and ulcerative colitis. Both forms of inflammatory bowel disease result from inappropriate inflammatory responses to the intestinal microbiota, but have different underlying immune...

  • Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. Torres, M. I.; Riós, A.; A. Crusius, J. Bart // World Journal of Gastroenterology;4/7/2008, Vol. 14 Issue 13, p1972 

    Although the aetiology of inflammatory bowel disease (IBD) remains unknown, the pathogenesis is gradually being unravelled, seeming to be the result of a combination of environmental, genetic, and immunological factors in which an uncontrolled immune response within the intestinal lumen leads to...

  • Interleukin-23 and Th17 Cells in the Control of Gut Inflammation. Monteleone, Ivan; Pallone, Francesco; Monteleone, Giovanni // Mediators of Inflammation;2009, Vol. 2009, Special section p1 

    Crohn's Disease and Ulcerative Colitis, the major forms of inflammatory bowel diseases (IBDs) in humans, have been traditionally associated with exaggerated and poorly controlled T helper (Th) type 1 or Th2 cell response, respectively. More recent studies have, however, shown that IBDs are also...

  • Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. de Mattos, Bruno Rafael Ramos; Garcia, Maellin Pereira Gracindo; Nogueira, Julia Bier; Paiatto, Lisiery Negrini; Albuquerque, Cassia Galdino; Souza, Caique Lopes; Fernandes, Luís Gustavo Romani; Tamashiro, Wirla Maria da Silva Cunha; Simioni, Patricia Ucelli // Mediators of Inflammation;8/3/2015, Vol. 2015, p1 

    Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn’s disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due...

  • A national survey on the patterns of treatment of inflammatory bowel disease in Canada. Hilsden, Robert J.; Verhoef, Marja J.; Best, Allan; Pocobelli, Gaia // BMC Gastroenterology;2003, Vol. 3, p10 

    Background: There is a general lack of information on the care of inflammatory bowel disease (IBD) in a broad, geographically diverse, non-clinic population. The purposes of this study were (1) to compare a sample drawn from the membership of a national Crohn's and Colitis Foundation to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics